| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/30/2023 | 257.14% | RBC Capital | → $25 | Initiates Coverage On | → Outperform |
| 04/03/2023 | 214.29% | Credit Suisse | $21 → $22 | Maintains | Outperform |
| 01/06/2023 | 200% | Credit Suisse | → $21 | Initiates Coverage On | → Outperform |
| 12/20/2022 | 171.43% | SVB Leerink | → $19 | Initiates Coverage On | → Outperform |
| 12/19/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/19/2022 | 242.86% | Jefferies | → $24 | Initiates Coverage On | → Buy |
What is the target price for NewAmsterdam Pharma (NAMS)?
The latest price target for NewAmsterdam Pharma (NASDAQ: NAMS) was reported by RBC Capital on October 30, 2023. The analyst firm set a price target for $25.00 expecting NAMS to rise to within 12 months (a possible 257.14% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NewAmsterdam Pharma (NAMS)?
The latest analyst rating for NewAmsterdam Pharma (NASDAQ: NAMS) was provided by RBC Capital, and NewAmsterdam Pharma initiated their outperform rating.
When is the next analyst rating going to be posted or updated for NewAmsterdam Pharma (NAMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NewAmsterdam Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NewAmsterdam Pharma was filed on October 30, 2023 so you should expect the next rating to be made available sometime around October 30, 2024.
Is the Analyst Rating NewAmsterdam Pharma (NAMS) correct?
While ratings are subjective and will change, the latest NewAmsterdam Pharma (NAMS) rating was a initiated with a price target of $0.00 to $25.00. The current price NewAmsterdam Pharma (NAMS) is trading at is $7.00, which is within the analyst's predicted range.